Clinical-development physician must resolve whether the 505(b)(2) bridge

Situation

A company with a CMC site change mid-review cannot treat a CRL citing manufacturing, not efficacy as color commentary on CMC comparability package for a site change. Clinical-development physician must close the 505(b)(2) bridge is from that extract under Pharma & Life Sciences / FDA Response and Labeling.

Decision

Clinical-development physician in a company with a CMC site change mid-review must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after a CRL citing manufacturing, not efficacy.

Hypotheses to test

• Authorize Proceed under protocol now; CMC comparability package for a site change already has the discriminator after a CRL citing manufacturing, not efficacy.
• Keep Pause the pathway in force until CMC comparability package for a site change is completed after a CRL citing manufacturing, not efficacy for clinical-development physician.
• Treat CMC comparability package for a site change as Escalate safety review because both readings appear after a CRL citing manufacturing, not efficacy.
• Refuse a Pharma & Life Sciences close: clinical-development physician does not have the page the 505(b)(2) bridge is turns on in CMC comparability package for a site change.

Analysis required

• Check whether CMC comparability package for a site change supports the labeled claim clinical-development physician would keep.
• Map FDA-response timing and owner in a company with a CMC site change mid-review.
• Trace CMC, labeling, or pharmacovigilance facts in CMC comparability package for a site change after a CRL citing manufacturing, not efficacy.
• For this Pharma & Life Sciences FDA Response and Labeling file, read CMC comparability package for a site change against a CRL citing manufacturing, not efficacy and write the one fact that would move the 505(b)(2) bridge is for clinical-development physician.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (CMC comparability package for a site change after a CRL citing manufacturing, not efficacy). The follow-on FDA Response and Labeling action is what clinical-development physician does next: implement the option, assign an owner, and log the missing fact.